The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification

Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected t...

Full description

Saved in:
Bibliographic Details
Published inCancer cell international Vol. 24; no. 1; p. 120
Main Authors Weng, Lijuan, Zhou, Jianliang, Guo, Shenchao, Xu, Nong, Ma, Ruishuang
Format Journal Article
LanguageEnglish
Published England BioMed Central 30.03.2024
BMC
Subjects
Androgen receptors
Androgens
Angiogenesis
Breast cancer
Cancer therapies
Cell cycle
Classification
Clinical trials
Cytokines
Epidermal growth factor
Gene expression
Genomes
Kinases
Medical prognosis
Metabolomics
Metastases
MicroRNAs
Molecular subtyping
Mutation
Precision medicine
Transcriptomics
Triple-negative breast cancer
Tumors
Molecular subtyping
Precision medicine
Triple-negative breast cancer
Online AccessGet full text

Cover

Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
AbstractList Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
ArticleNumber 120
Author Zhou, Jianliang
Guo, Shenchao
Weng, Lijuan
Xu, Nong
Ma, Ruishuang
Author_xml – sequence: 1
  givenname: Lijuan
  surname: Weng
  fullname: Weng, Lijuan
  organization: Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo, China
– sequence: 2
  givenname: Jianliang
  surname: Zhou
  fullname: Zhou, Jianliang
  organization: Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo, China
– sequence: 3
  givenname: Shenchao
  surname: Guo
  fullname: Guo, Shenchao
  organization: Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo, China
– sequence: 4
  givenname: Nong
  surname: Xu
  fullname: Xu, Nong
  email: nongxu@zju.edu.cn
  organization: Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China. nongxu@zju.edu.cn
– sequence: 5
  givenname: Ruishuang
  surname: Ma
  fullname: Ma, Ruishuang
  email: mars6318@163.com
  organization: Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo, China. mars6318@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38555429$$D View this record in MEDLINE/PubMed
BookMark eNpdkU9vFCEYh4mpse3qF_BgSLx4Qfk_zFE31jZp9LKeCQPvrGxmYYSZJv32Yrc2phcg5Pn98sJzic5SToDQW0Y_Mmb0p8p4LxShXBIquGaEvkAXTHaKcKO7s__O5-iy1gOlrDOavkLnwiilJO8v0LL7BfiYJ_Dr5Aqu67DczzHtsUsBzwV8rDEnfIQQfUyAY8JLifMEJMHeLfEO8FDA1QV7lzwUQsjgKgTcQldrcAnvvn_ZYj-5WuMYfYvk9Bq9HN1U4c3jvkE_r77uttfk9se3m-3nW-LbcAvhgRnDwbNOB6nHTktqjHOaioFLGQwDzaUTTOr2FDl2yjSAD9pAr8ZeGLFBN6fekN3BziUeXbm32UX7cJHL3rqyRD-Bhc5II1XHDDgp-dAPqleBqVELxttnta4Pp6655N8r1MUeY_UwTS5BXqsVlPMW10w09P0z9JDXktpLGyWaAsN13yh-onzJtRYYnwZk1P71a09-bfNrH_y2dYPePVavQ3PyFPknVPwB_CSfWw
CitedBy_id crossref_primary_10_3390_ijms25137044
Cites_doi 10.3892/mmr.2016.6019
10.1016/j.ctrv.2018.06.005
10.1158/2159-8290.CD-11-0348
10.3390/cancers9010004
10.1186/s13058-018-1041-8
10.1007/s11427-021-2140-8
10.1007/s10549-019-05156-5
10.1158/1078-0432.CCR-07-4756
10.1158/0008-5472.CAN-09-4120
10.1038/s41467-023-38115-2
10.1016/j.ccell.2023.01.004
10.1007/s10555-021-09972-4
10.1371/journal.pone.0082650
10.1038/nrc3818
10.1097/PPO.0b013e3181ce4ae1
10.1016/j.ccell.2016.09.002
10.1038/ng.2481
10.1007/s00428-022-03329-0
10.1093/jnci/djv148
10.1631/jzus.B1900709
10.1038/s41422-020-0375-9
10.1016/j.cmet.2019.08.013
10.1158/1078-0432.CCR-15-3036
10.1056/NEJMoa1809615
10.1016/j.cmet.2018.09.002
10.3389/pore.2023.1611162
10.1038/s41416-019-0650-z
10.1016/j.clbc.2020.06.011
10.1634/theoncologist.2012-0397
10.1038/nrclinonc.2016.60
10.1200/JCO.2016.71.3495
10.1001/jamaoncol.2018.4475
10.1056/NEJMoa1513749
10.1038/s41422-023-00795-2
10.1038/s41422-022-00614-0
10.5483/BMBRep.2017.50.3.222
10.1038/nature12108
10.1093/annonc/mdq430
10.1016/j.cmet.2020.10.012
10.1038/s41571-021-00565-2
10.1200/JCO.2018.77.8738
10.1158/1078-0432.CCR-15-2477
10.1074/jbc.M807438200
10.1016/j.cmet.2018.06.003
10.1016/j.cels.2017.12.014
10.1053/j.gastro.2013.09.050
10.1097/CM9.0000000000002056
10.1016/j.anndiagpath.2022.151901
10.1158/0008-5472.CAN-13-1841
10.1056/NEJMoa2105215
10.1158/1078-0432.CCR-12-3327
10.1093/annonc/mdw067
10.1186/s13058-014-0406-x
10.1158/1078-0432.CCR-14-1209
10.1101/gad.1756509
10.1084/jem.20120162
10.1016/j.lfs.2019.05.076
10.1016/j.ccell.2015.12.004
10.1371/journal.pone.0157368
10.7150/thno.36182
10.1186/s13059-015-0620-6
10.1016/j.ccell.2019.02.001
10.3390/cancers6031351
10.1158/0008-5472.CAN-12-1699
10.1016/j.cell.2022.09.020
10.1038/srep46079
10.1172/JCI45014
10.1126/science.1160809
10.18632/oncotarget.10208
10.1038/nrclinonc.2016.26
10.1371/journal.pone.0197827
10.4048/jbc.2015.18.2.134
10.1155/2019/1061979
10.1634/theoncologist.2019-0982
10.3389/fonc.2020.01787
10.1158/1078-0432.CCR-14-0432
10.1038/nature11412
10.1016/j.cmet.2022.09.021
10.1074/jbc.M805186200
10.1001/jamaoncol.2018.5152
10.1093/annonc/mdu112
10.1073/pnas.0403390101
10.1073/pnas.1424171112
10.1074/jbc.M115.660498
10.1016/j.cell.2009.01.002
10.1007/s11427-020-1714-8
10.1016/j.cmet.2016.08.011
10.1158/2159-8290.CD-12-0349
ContentType Journal Article
Copyright 2024. The Author(s).
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024. The Author(s).
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID NPM
AAYXX
CITATION
3V.
7TM
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOA
DOI 10.1186/s12935-024-03261-0
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest - Health & Medical Complete保健、医学与药学数据库
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
CrossRef
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: ProQuest Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1475-2867
EndPage 120
ExternalDocumentID oai_doaj_org_article_e784845718ea442b9b595d15f6312555
10_1186_s12935_024_03261_0
38555429
Genre Journal Article
Review
GrantInformation_xml – fundername: National Natural Science Foundation of Zhejiang Province
  grantid: LY23H160008
– fundername: Ningbo Natural Science Foundation
  grantid: 202003N4285
– fundername: Ningbo Natural Science Foundation
  grantid: 2023J146
GroupedDBID ---
-56
-5G
-A0
-BR
0R~
29B
2WC
3V.
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
ISR
ITC
KQ8
LGEZI
LOTEE
M~E
NADUK
NPM
NXXTH
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
AAYXX
CITATION
7TM
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
M48
PQEST
PQUKI
PRINS
7X8
AFGXO
ID FETCH-LOGICAL-c542t-2d1882ec176d46f764088aa603b244d81e624a31464294f7584082b68e95f9383
IEDL.DBID 7X7
ISSN 1475-2867
IngestDate Fri Oct 04 13:10:43 EDT 2024
Sat Aug 17 05:38:04 EDT 2024
Thu Oct 10 18:07:30 EDT 2024
Thu Sep 12 17:26:47 EDT 2024
Sun Oct 13 09:24:04 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Molecular subtyping
Precision medicine
Triple-negative breast cancer
Language English
License 2024. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c542t-2d1882ec176d46f764088aa603b244d81e624a31464294f7584082b68e95f9383
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://www.proquest.com/docview/3037868269?pq-origsite=%requestingapplication%
PMID 38555429
PQID 3037868269
PQPubID 42567
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_e784845718ea442b9b595d15f6312555
proquest_miscellaneous_3022571613
proquest_journals_3037868269
crossref_primary_10_1186_s12935_024_03261_0
pubmed_primary_38555429
PublicationCentury 2000
PublicationDate 2024-03-30
PublicationDateYYYYMMDD 2024-03-30
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-30
  day: 30
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Cancer cell international
PublicationTitleAlternate Cancer Cell Int
PublicationYear 2024
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References L Xin (3261_CR24) 2022; 135
C Desmedt (3261_CR23) 2008; 14
A Brand (3261_CR84) 2016; 24
MG Vander Heiden (3261_CR75) 2009; 324
Y Shi (3261_CR33) 2017; 15
Y Liu (3261_CR59) 2023; 33
MD Burstein (3261_CR5) 2015; 21
G Bianchini (3261_CR1) 2022; 19
B O’Leary (3261_CR27) 2016; 13
KN Stevens (3261_CR46) 2013; 73
R Bose (3261_CR25) 2013; 3
IE Smith (3261_CR63) 2011; 22
YH Ibrahim (3261_CR51) 2012; 2
S Zhao (3261_CR39) 2020; 25
Q Huang (3261_CR62) 2022
3261_CR7
H Bonnefoi (3261_CR10) 2016; 27
WJ Zuo (3261_CR26) 2016; 22
P Schmid (3261_CR60) 2018; 379
BD Lehmann (3261_CR2) 2011; 121
TA Traina (3261_CR11) 2018; 36
RG Jones (3261_CR76) 2009; 23
H Yu (3261_CR53) 2014; 14
H Makinoshima (3261_CR82) 2015; 290
AA Hakimi (3261_CR72) 2016; 29
Y Asano (3261_CR17) 2017
F Coussy (3261_CR20) 2020; 10
H Liu (3261_CR56) 2019
Q Qu (3261_CR14) 2013
H Dvinge (3261_CR31) 2013; 497
SL Goff (3261_CR36) 2021
A Prat (3261_CR4) 2013; 18
T O’Meara (3261_CR35) 2019; 175
YZ Jiang (3261_CR6) 2019; 35
BD Lehmann (3261_CR3) 2016
J Lian (3261_CR37) 2022; 481
T Salisbury (3261_CR41) 2022
L Mulrane (3261_CR32) 2013; 73
J Xu (3261_CR88) 2020; 21
Z Cai (3261_CR28) 2023; 66
B Virassamy (3261_CR42) 2023
ML Telli (3261_CR47) 2016; 22
AT Ooi (3261_CR83) 2015; 21
Y Kim (3261_CR16) 2015; 18
J Bi (3261_CR18) 2023
Y Li (3261_CR40) 2015; 112
TW Jensen (3261_CR64) 2015
D Juric (3261_CR21) 2019
JM Bailey (3261_CR58) 2014; 146
J Kim (3261_CR73) 2019; 30
M Najafi (3261_CR54) 2019
Y Gong (3261_CR78) 2021
N Koundouros (3261_CR81) 2020; 122
RB Hamanaka (3261_CR77) 2012; 209
Y Nakanishi (3261_CR57) 2013; 45
S Loi (3261_CR61) 2014; 25
F Yang (3261_CR87) 2023
AC Wolff (3261_CR22) 2018; 36
K Astvatsaturyan (3261_CR12) 2018
CE Lau (3261_CR79) 2017
AL Heeke (3261_CR43) 2021; 40
SY Wu (3261_CR52) 2021; 64
YZ Jiang (3261_CR66) 2021; 31
NE Muvarak (3261_CR50) 2016; 30
M Leeha (3261_CR38) 2023
S Adams (3261_CR44) 2019; 5
JA Menendez (3261_CR80) 2004; 101
UE Martinez-Outschoorn (3261_CR71) 2017
K Eun (3261_CR55) 2017; 50
EV Berdyshev (3261_CR86) 2009; 284
M Pistelli (3261_CR13) 2014; 6
M Angelova (3261_CR34) 2015
DP Bartel (3261_CR30) 2009; 136
S Lahiri (3261_CR85) 2009; 284
G Gentric (3261_CR69) 2019
Cancer Genome Atlas Network (3261_CR29) 2012; 490
Y Xiao (3261_CR67) 2022; 32
HS Rugo (3261_CR49) 2016; 375
L Gerratana (3261_CR8) 2018; 68
A Gucalp (3261_CR9) 2013; 19
E Reznik (3261_CR74) 2018
C Wang (3261_CR15) 2016; 7
PS Ray (3261_CR65) 2010; 70
T Du (3261_CR68) 2018
BD Lehmann (3261_CR19) 2014
A Daemen (3261_CR70) 2018
J Zhang (3261_CR45) 2020
ANJ Tutt (3261_CR48) 2021; 384
References_xml – volume: 15
  start-page: 29
  issue: 1
  year: 2017
  ident: 3261_CR33
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2016.6019
  contributor:
    fullname: Y Shi
– volume: 68
  start-page: 102
  year: 2018
  ident: 3261_CR8
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2018.06.005
  contributor:
    fullname: L Gerratana
– volume: 2
  start-page: 1036
  issue: 11
  year: 2012
  ident: 3261_CR51
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-11-0348
  contributor:
    fullname: YH Ibrahim
– year: 2017
  ident: 3261_CR17
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers9010004
  contributor:
    fullname: Y Asano
– year: 2018
  ident: 3261_CR68
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-018-1041-8
  contributor:
    fullname: T Du
– volume: 66
  start-page: 94
  issue: 1
  year: 2023
  ident: 3261_CR28
  publication-title: Sci China Life Sci
  doi: 10.1007/s11427-021-2140-8
  contributor:
    fullname: Z Cai
– volume: 175
  start-page: 247
  issue: 1
  year: 2019
  ident: 3261_CR35
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-019-05156-5
  contributor:
    fullname: T O’Meara
– volume: 14
  start-page: 5158
  issue: 16
  year: 2008
  ident: 3261_CR23
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4756
  contributor:
    fullname: C Desmedt
– volume: 70
  start-page: 3870
  issue: 10
  year: 2010
  ident: 3261_CR65
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-4120
  contributor:
    fullname: PS Ray
– year: 2023
  ident: 3261_CR18
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-38115-2
  contributor:
    fullname: J Bi
– year: 2023
  ident: 3261_CR42
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2023.01.004
  contributor:
    fullname: B Virassamy
– volume: 40
  start-page: 537
  issue: 2
  year: 2021
  ident: 3261_CR43
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-021-09972-4
  contributor:
    fullname: AL Heeke
– year: 2013
  ident: 3261_CR14
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0082650
  contributor:
    fullname: Q Qu
– volume: 14
  start-page: 736
  issue: 11
  year: 2014
  ident: 3261_CR53
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3818
  contributor:
    fullname: H Yu
– ident: 3261_CR7
  doi: 10.1097/PPO.0b013e3181ce4ae1
– volume: 30
  start-page: 637
  issue: 4
  year: 2016
  ident: 3261_CR50
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.002
  contributor:
    fullname: NE Muvarak
– volume: 45
  start-page: 98
  issue: 1
  year: 2013
  ident: 3261_CR57
  publication-title: Nat Genet
  doi: 10.1038/ng.2481
  contributor:
    fullname: Y Nakanishi
– volume: 481
  start-page: 13
  issue: 1
  year: 2022
  ident: 3261_CR37
  publication-title: Virchows Arch
  doi: 10.1007/s00428-022-03329-0
  contributor:
    fullname: J Lian
– year: 2015
  ident: 3261_CR64
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djv148
  contributor:
    fullname: TW Jensen
– volume: 21
  start-page: 673
  issue: 9
  year: 2020
  ident: 3261_CR88
  publication-title: J Zhejiang Univ Sci B
  doi: 10.1631/jzus.B1900709
  contributor:
    fullname: J Xu
– volume: 31
  start-page: 178
  issue: 2
  year: 2021
  ident: 3261_CR66
  publication-title: Cell Res
  doi: 10.1038/s41422-020-0375-9
  contributor:
    fullname: YZ Jiang
– volume: 30
  start-page: 434
  issue: 3
  year: 2019
  ident: 3261_CR73
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2019.08.013
  contributor:
    fullname: J Kim
– volume: 22
  start-page: 4859
  issue: 19
  year: 2016
  ident: 3261_CR26
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-3036
  contributor:
    fullname: WJ Zuo
– volume: 379
  start-page: 2108
  issue: 22
  year: 2018
  ident: 3261_CR60
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1809615
  contributor:
    fullname: P Schmid
– year: 2019
  ident: 3261_CR69
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.09.002
  contributor:
    fullname: G Gentric
– year: 2023
  ident: 3261_CR38
  publication-title: Pathol Oncol Res
  doi: 10.3389/pore.2023.1611162
  contributor:
    fullname: M Leeha
– volume: 122
  start-page: 4
  issue: 1
  year: 2020
  ident: 3261_CR81
  publication-title: Br J Cancer
  doi: 10.1038/s41416-019-0650-z
  contributor:
    fullname: N Koundouros
– year: 2021
  ident: 3261_CR36
  publication-title: Clin Breast Cancer
  doi: 10.1016/j.clbc.2020.06.011
  contributor:
    fullname: SL Goff
– volume: 18
  start-page: 123
  issue: 2
  year: 2013
  ident: 3261_CR4
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2012-0397
  contributor:
    fullname: A Prat
– year: 2017
  ident: 3261_CR71
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.60
  contributor:
    fullname: UE Martinez-Outschoorn
– volume: 36
  start-page: 884
  issue: 9
  year: 2018
  ident: 3261_CR11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.71.3495
  contributor:
    fullname: TA Traina
– year: 2019
  ident: 3261_CR21
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.4475
  contributor:
    fullname: D Juric
– volume: 375
  start-page: 23
  issue: 1
  year: 2016
  ident: 3261_CR49
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1513749
  contributor:
    fullname: HS Rugo
– volume: 33
  start-page: 389
  issue: 5
  year: 2023
  ident: 3261_CR59
  publication-title: Cell Res
  doi: 10.1038/s41422-023-00795-2
  contributor:
    fullname: Y Liu
– volume: 32
  start-page: 477
  issue: 5
  year: 2022
  ident: 3261_CR67
  publication-title: Cell Res
  doi: 10.1038/s41422-022-00614-0
  contributor:
    fullname: Y Xiao
– volume: 50
  start-page: 117
  issue: 3
  year: 2017
  ident: 3261_CR55
  publication-title: BMB Rep
  doi: 10.5483/BMBRep.2017.50.3.222
  contributor:
    fullname: K Eun
– volume: 497
  start-page: 378
  issue: 7449
  year: 2013
  ident: 3261_CR31
  publication-title: Nature
  doi: 10.1038/nature12108
  contributor:
    fullname: H Dvinge
– volume: 22
  start-page: 595
  issue: 3
  year: 2011
  ident: 3261_CR63
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq430
  contributor:
    fullname: IE Smith
– year: 2021
  ident: 3261_CR78
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2020.10.012
  contributor:
    fullname: Y Gong
– volume: 19
  start-page: 91
  issue: 2
  year: 2022
  ident: 3261_CR1
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00565-2
  contributor:
    fullname: G Bianchini
– volume: 36
  start-page: 2105
  issue: 20
  year: 2018
  ident: 3261_CR22
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.77.8738
  contributor:
    fullname: AC Wolff
– volume: 22
  start-page: 3764
  issue: 15
  year: 2016
  ident: 3261_CR47
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2477
  contributor:
    fullname: ML Telli
– volume: 284
  start-page: 16090
  issue: 24
  year: 2009
  ident: 3261_CR85
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M807438200
  contributor:
    fullname: S Lahiri
– year: 2018
  ident: 3261_CR70
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.06.003
  contributor:
    fullname: A Daemen
– year: 2018
  ident: 3261_CR74
  publication-title: Cell Syst
  doi: 10.1016/j.cels.2017.12.014
  contributor:
    fullname: E Reznik
– volume: 146
  start-page: 245
  issue: 1
  year: 2014
  ident: 3261_CR58
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.09.050
  contributor:
    fullname: JM Bailey
– volume: 135
  start-page: 697
  issue: 6
  year: 2022
  ident: 3261_CR24
  publication-title: Chin Med J (Engl)
  doi: 10.1097/CM9.0000000000002056
  contributor:
    fullname: L Xin
– year: 2022
  ident: 3261_CR41
  publication-title: Ann Diagn Pathol
  doi: 10.1016/j.anndiagpath.2022.151901
  contributor:
    fullname: T Salisbury
– volume: 73
  start-page: 6554
  issue: 22
  year: 2013
  ident: 3261_CR32
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-1841
  contributor:
    fullname: L Mulrane
– volume: 384
  start-page: 2394
  issue: 25
  year: 2021
  ident: 3261_CR48
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2105215
  contributor:
    fullname: ANJ Tutt
– volume: 19
  start-page: 5505
  issue: 19
  year: 2013
  ident: 3261_CR9
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-3327
  contributor:
    fullname: A Gucalp
– volume: 27
  start-page: 812
  issue: 5
  year: 2016
  ident: 3261_CR10
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw067
  contributor:
    fullname: H Bonnefoi
– year: 2014
  ident: 3261_CR19
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-014-0406-x
  contributor:
    fullname: BD Lehmann
– volume: 21
  start-page: 2440
  issue: 11
  year: 2015
  ident: 3261_CR83
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-1209
  contributor:
    fullname: AT Ooi
– volume: 23
  start-page: 537
  issue: 5
  year: 2009
  ident: 3261_CR76
  publication-title: Genes Dev
  doi: 10.1101/gad.1756509
  contributor:
    fullname: RG Jones
– volume: 209
  start-page: 211
  issue: 2
  year: 2012
  ident: 3261_CR77
  publication-title: J Exp Med
  doi: 10.1084/jem.20120162
  contributor:
    fullname: RB Hamanaka
– year: 2019
  ident: 3261_CR54
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2019.05.076
  contributor:
    fullname: M Najafi
– volume: 29
  start-page: 104
  issue: 1
  year: 2016
  ident: 3261_CR72
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.12.004
  contributor:
    fullname: AA Hakimi
– year: 2016
  ident: 3261_CR3
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0157368
  contributor:
    fullname: BD Lehmann
– volume: 10
  start-page: 1531
  issue: 4
  year: 2020
  ident: 3261_CR20
  publication-title: Theranostics
  doi: 10.7150/thno.36182
  contributor:
    fullname: F Coussy
– year: 2015
  ident: 3261_CR34
  publication-title: Genome Biol
  doi: 10.1186/s13059-015-0620-6
  contributor:
    fullname: M Angelova
– volume: 35
  start-page: 428
  issue: 3
  year: 2019
  ident: 3261_CR6
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.02.001
  contributor:
    fullname: YZ Jiang
– volume: 6
  start-page: 1351
  issue: 3
  year: 2014
  ident: 3261_CR13
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers6031351
  contributor:
    fullname: M Pistelli
– volume: 73
  start-page: 2025
  issue: 7
  year: 2013
  ident: 3261_CR46
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-1699
  contributor:
    fullname: KN Stevens
– year: 2022
  ident: 3261_CR62
  publication-title: Cell
  doi: 10.1016/j.cell.2022.09.020
  contributor:
    fullname: Q Huang
– year: 2017
  ident: 3261_CR79
  publication-title: Sci Rep
  doi: 10.1038/srep46079
  contributor:
    fullname: CE Lau
– volume: 121
  start-page: 2750
  issue: 7
  year: 2011
  ident: 3261_CR2
  publication-title: J Clin Invest
  doi: 10.1172/JCI45014
  contributor:
    fullname: BD Lehmann
– volume: 324
  start-page: 1029
  issue: 5930
  year: 2009
  ident: 3261_CR75
  publication-title: Science
  doi: 10.1126/science.1160809
  contributor:
    fullname: MG Vander Heiden
– volume: 7
  start-page: 46482
  issue: 29
  year: 2016
  ident: 3261_CR15
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10208
  contributor:
    fullname: C Wang
– volume: 13
  start-page: 417
  issue: 7
  year: 2016
  ident: 3261_CR27
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.26
  contributor:
    fullname: B O’Leary
– year: 2018
  ident: 3261_CR12
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0197827
  contributor:
    fullname: K Astvatsaturyan
– volume: 18
  start-page: 134
  issue: 2
  year: 2015
  ident: 3261_CR16
  publication-title: J Breast Cancer
  doi: 10.4048/jbc.2015.18.2.134
  contributor:
    fullname: Y Kim
– year: 2019
  ident: 3261_CR56
  publication-title: Biomed Res Int
  doi: 10.1155/2019/1061979
  contributor:
    fullname: H Liu
– volume: 25
  start-page: e1481
  issue: 10
  year: 2020
  ident: 3261_CR39
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2019-0982
  contributor:
    fullname: S Zhao
– year: 2020
  ident: 3261_CR45
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.01787
  contributor:
    fullname: J Zhang
– volume: 21
  start-page: 1688
  issue: 7
  year: 2015
  ident: 3261_CR5
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-0432
  contributor:
    fullname: MD Burstein
– volume: 490
  start-page: 61
  issue: 7418
  year: 2012
  ident: 3261_CR29
  publication-title: Nature
  doi: 10.1038/nature11412
  contributor:
    fullname: Cancer Genome Atlas Network
– year: 2023
  ident: 3261_CR87
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2022.09.021
  contributor:
    fullname: F Yang
– volume: 284
  start-page: 5467
  issue: 9
  year: 2009
  ident: 3261_CR86
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M805186200
  contributor:
    fullname: EV Berdyshev
– volume: 5
  start-page: 334
  issue: 3
  year: 2019
  ident: 3261_CR44
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.5152
  contributor:
    fullname: S Adams
– volume: 25
  start-page: 1544
  issue: 8
  year: 2014
  ident: 3261_CR61
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu112
  contributor:
    fullname: S Loi
– volume: 101
  start-page: 10715
  issue: 29
  year: 2004
  ident: 3261_CR80
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0403390101
  contributor:
    fullname: JA Menendez
– volume: 112
  start-page: 1839
  issue: 6
  year: 2015
  ident: 3261_CR40
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1424171112
  contributor:
    fullname: Y Li
– volume: 290
  start-page: 17495
  issue: 28
  year: 2015
  ident: 3261_CR82
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M115.660498
  contributor:
    fullname: H Makinoshima
– volume: 136
  start-page: 215
  issue: 2
  year: 2009
  ident: 3261_CR30
  publication-title: Cell
  doi: 10.1016/j.cell.2009.01.002
  contributor:
    fullname: DP Bartel
– volume: 64
  start-page: 372
  issue: 3
  year: 2021
  ident: 3261_CR52
  publication-title: Sci China Life Sci
  doi: 10.1007/s11427-020-1714-8
  contributor:
    fullname: SY Wu
– volume: 24
  start-page: 657
  issue: 5
  year: 2016
  ident: 3261_CR84
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2016.08.011
  contributor:
    fullname: A Brand
– volume: 3
  start-page: 224
  issue: 2
  year: 2013
  ident: 3261_CR25
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0349
  contributor:
    fullname: R Bose
SSID ssj0017860
Score 2.4013126
SecondaryResourceType review_article
Snippet Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and...
Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients...
Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients...
SourceID doaj
proquest
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 120
SubjectTerms Androgen receptors
Androgens
Angiogenesis
Breast cancer
Cancer therapies
Cell cycle
Classification
Clinical trials
Cytokines
Epidermal growth factor
Gene expression
Genomes
Kinases
Medical prognosis
Metabolomics
Metastases
MicroRNAs
Molecular subtyping
Mutation
Precision medicine
Transcriptomics
Triple-negative breast cancer
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4iCF7Et-uLCN4k2DSPpkcVFxH0pOAtJJtEPFhlt3vYf-9M0y56EC9e27QM8yXzzSSTGULOa88VEFNkMCEik8HVzFW-ZEXyvAg-chNxa-DhUd89y_sX9fKt1RfmhOXywFlxl7Ey0kgFJjQ6KUtfe1WrwFXSArhZ5eqlXA3BVH9-UBldDFdkjL6cIavhTWTJCoE7LsUPGuqq9f_uYnZUM94kG72PSK-ybFtkJTbbZC13jVzskBagpe9DW1s6m_t2gbeeqGsC_Zz2TXPocGpO3xraTnE_nTXxtavzTT2mord0gpBPGWPIZYHCR-N5cA19ery-oRP0qzGRqMNulzyPb59u7ljfPIFNlCxbVgYOznOc8EoHqVOlJdgT53QhPDB6MDzqUjoBhhIYSSYIG7D1tNcm1irVELfukdXmo4kHhJbJS-lMKlOAcEwp42qRYhWECCFUqh6Ri0GX9jPXyLBdbGG0zZq3oHnbad4WI3KN6l6OxPrW3QNA3fao279QH5HjASzbL7qZBTYG3CFeAonOlq9hueAZiGvixxzHgAGDGJGLEdnPIC8lEQb-DNo4_A8Jj8h6mecbE8UxWW2n83gC_kvrT7up-gUttuf1
  priority: 102
  providerName: Directory of Open Access Journals
Title The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
URI https://www.ncbi.nlm.nih.gov/pubmed/38555429
https://www.proquest.com/docview/3037868269
https://search.proquest.com/docview/3022571613
https://doaj.org/article/e784845718ea442b9b595d15f6312555
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtQqGXkr6dpIsKvRURy3pYPoVuyBICWUpIYOlFSJYceoh36_Ue8u87I9tbemgvPtiSMDOj-b4ZPYaQL5XnCoApMjCIyGRwFXOlL1jeeJ4HH7mJmBq4Weqre3m9Uqsx4bYdt1VOPjE56rCuMUd-Bq62NBrIcHW--cWwahSuro4lNJ6TQ14AmQB7Llf7gItDh3w6KGP02RaxDc8jS5YLzLvkf4FRurP_30QzAc7iiLwamSL9Nqj2NXkW2zfkxVA78ukt6UHB9HEqbku3O98_4dkn6tpAN91YOodOa-f0Z0v7DrPqrI0P6bZv6nFDek9rVHzHGENECxQ6LXbBtfRuOb-gNbJr3E6UNPiO3C8u7y6u2FhCgdVKFj0rAgcKHWte6iB1U2oJXsU5nQsPuB4Mj7qQToC7BFySDQQPWIDaaxMr1VQQvb4nB-26jR8JLRovpTNN0QQIypQyrhJNLIMQIYRSVRn5OsnSboabMmyKMIy2g-QtSN4myds8I3MU974l3nKdXqy7BztOGhtLI41UAJ_RSVn4yqtKBa4aLYCXKZWR00lZdpx6W_vHUDLyef8ZJg2uhLg2rnfYBtwYRIpcZOTDoOT9nwgDI4M0jv8_-Al5WQyWxER-Sg76bhc_AT_p_SwZ4Ywczi-X329nKcqH5-38x29yvuTH
link.rule.ids 315,786,790,870,2115,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCNELojwDbTESN2Q1iR-xT4hWXS3Q7mkr7c2yY7vqgeySzR767zuTxyIOcI0fimbG882MxzOEfDa-kABMkYFARCaCM8xVvmR58kUefCx0xNDA9ULNb8SPlVyNAbftmFY56cReUYd1jTHyM1C1lVZgDJuvm98Mu0bh7erYQuMxeSI4F5jSV632DlcBC_LpoYxWZ1vENnyPLFjOMe6S_wVGfc3-fxuaPeDMXpDno6VIvw2sPSKPYvOSPB16R96_Ih0wmP6amtvS7c539_j2ibom0E07ts6h0905vWto12JUnTXxtq_2TT0mpHe0Rsa3jDFEtEBh0WwXXEOXi_MLWqN1jelEPQdfk5vZ5fJizsYWCqyWouxYGQowoWNdVCoIlSolQKs4p3LuAdeDLqIqheOgLgGXRALnARtQe6WjkcmA9_qGHDTrJr4jtExeCKdTmQI4ZVJqZ3iKVeA8hFBJk5EvEy3tZqiUYXsPQys7UN4C5W1PeZtn5BzJvZ-JVa77D-v21o6HxsZKCy0kwGd0QpTeeGlkKGRSHOwyKTNyPDHLjkdva_8ISkY-7Yfh0OBNiGvieodzQI2Bp1jwjLwdmLz_E65hZ6DG-_9v_pE8my-vr-zV98XPD-SwHKSK8fyYHHTtLp6ArdL5014gHwB0y-QY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+molecular+subtyping+and+precision+medicine+in+triple-negative+breast+cancer---based+on+Fudan+TNBC+classification&rft.jtitle=Cancer+cell+international&rft.au=Weng%2C+Lijuan&rft.au=Zhou%2C+Jianliang&rft.au=Guo%2C+Shenchao&rft.au=Xu%2C+Nong&rft.date=2024-03-30&rft.issn=1475-2867&rft.eissn=1475-2867&rft.volume=24&rft.issue=1&rft.spage=120&rft_id=info:doi/10.1186%2Fs12935-024-03261-0&rft_id=info%3Apmid%2F38555429&rft.externalDocID=38555429
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon